AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 225.40

Change

-3.01 (-1.32)%

Market Cap

USD 122.18B

Volume

2.54M

Avg Analyst Target

USD 240.92 (+6.89%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AMGN Stock Forecast & Price:
Based on the Amgen Inc stock forecasts from 10 analysts, the average analyst target price for Amgen Inc is USD 240.92 over the next 12 months. Amgen Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Amgen Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Amgen Inc’s stock price was USD 225.40. Amgen Inc’s stock price has changed by -0.69% over the past week, -5.74% over the past month and +6.00% over the last year.

About Amgen Inc (AMGN:NSD)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheu ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-30 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC ADR

-0.07 (-0.13%)

USD180.73B 1,689.87 28.08
SNY Sanofi ADR

+0.02 (+0.05%)

USD96.62B 14.68 10.85
GILD Gilead Sciences Inc

-1.38 (-2.19%)

USD78.50B 19.15 11.52
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

+2.72 (+1.03%)

USD40.14B 20.06 10.07
HZNP Horizon Pharma PLC

-0.80 (-1.28%)

USD14.51B 19.32 12.37
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
GRFS Grifols SA ADR

+0.21 (+3.53%)

USD5.55B 72.06 16.14
TSVTV 2seventy bio Inc. Common Stock..

N/A

USD0.62B N/A N/A
CRXT Clarus Therapeutics Holdings I..

N/A

USD2.47M N/A -1.04

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
UBIO ProShares UltraPro Nasdaq.. 6.41 % 0.95 %

N/A

USD0.02B
SXRU:XETRA iShares VII PLC - iShares.. 0.00 % 0.33 %

+0.20 (+0.06%)

USD0.86B
EKUS:PA BNP Paribas Easy MSCI USA.. 0.00 % 0.18 %

+0.14 (+0.86%)

USD1.00B
3SUR:F iShares IV Public Limited.. 0.00 % 0.23 %

-6.60 (-0.50%)

N/A
BBCK:F Invesco Markets III plc -.. 0.00 % 0.39 %

-0.64 (-1.66%)

USD0.06B
EMWE:F BNP Paribas Easy - MSCI W.. 0.00 % 0.13 %

-0.17 (-1.08%)

N/A
EXI3:F iShares Dow Jones Industr.. 0.00 % 0.51 %

-5.75 (-1.90%)

USD0.24B
MJMT:F Amundi Index Solutions - .. 0.00 % 0.13 %

+0.36 (+0.49%)

USD0.21B
SXRU:F iShares VII Public Limite.. 0.00 % 0.33 %

-6.70 (-1.90%)

USD0.86B
UIMP:F UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

-2.90 (-1.92%)

USD1.57B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.10 (+1.82%)

USD0.46B
BBCK:XETRA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.40 (+1.05%)

USD0.06B
EXI3:XETRA iShares Dow Jones Industr.. 0.00 % 0.51 %

+0.05 (+0.02%)

USD0.24B
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.73 (-0.52%)

USD0.44B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
UET1:XETRA UBS(Lux)Fund Solutions .. 0.00 % 0.33 %

+0.20 (+1.08%)

USD0.14B
UIMP:XETRA UBS MSCI USA Socially Res.. 0.00 % 0.33 %

+1.02 (+0.69%)

USD1.57B
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

N/A

USD0.05B
ZPAY:CA BMO Premium Yield ETF 0.00 % 0.65 %

-0.19 (-0.70%)

N/A
ESNG Direxion MSCI USA ESG - L.. 0.00 % 0.40 %

N/A

USD8.48M
TACE Trend Aggregation Conserv.. 0.00 % 1.87 %

N/A

USD0.02B
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
FLXX:LSE Franklin LibertyQ Global .. 0.00 % 0.45 %

-0.10 (-0.42%)

USD0.04B
FRGD:LSE Franklin LibertyQ Global .. 0.00 % 0.45 %

N/A

USD0.04B
FRGE:LSE Franklin LibertyQ Global .. 0.00 % 0.25 %

N/A

USD0.03B
ZPAY-F:CA BMO Premium Yield ETF 0.00 % 0.65 %

-0.32 (-1.27%)

USD0.05B
ZPAY-U:CA BMO Premium Yield ETF 0.00 % 0.65 %

N/A

N/A
BUYB:PA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.44 (+1.16%)

USD0.06B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
SBUY:LSE Invesco Global Buyback Ac.. 0.00 % 0.39 %

+12.00 (+0.36%)

USD0.06B
SCHD Schwab U.S. Dividend Equi.. 0.00 % 0.06 %

-0.80 (-1.19%)

USD37.12B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.10 (+0.40%)

USD8.39M
BLV Vanguard Long-Term Bond I.. 0.00 % 0.04 %

-0.42 (-0.58%)

USD8.30B
DDM ProShares Ultra Dow30 0.00 % 0.95 %

-1.75 (-3.46%)

USD0.34B
DIA SPDR® Dow Jones Industri.. 0.00 % 0.16 %

-4.91 (-1.68%)

USD27.39B
DJD Invesco Dow Jones Industr.. 0.00 % 0.07 %

-0.54 (-1.42%)

USD0.24B
FLQD Franklin LibertyQ Global .. 0.00 % 0.06 %

N/A

USD0.05B
IBB iShares Biotechnology ETF 0.00 % 0.44 %

-0.64 (-0.54%)

USD7.38B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+0.01 (+0.02%)

USD0.24B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

-0.71 (-0.99%)

USD0.31B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.39 (+2.65%)

USD6.17M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.39 (+2.65%)

USD6.17M
UDOW ProShares UltraPro Dow30 0.00 % 0.95 %

-2.08 (-5.11%)

USD0.55B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.16 (-0.33%)

USD0.08B
VVO:CA Vanguard Global Minimum V.. 0.00 % 0.36 %

N/A

USD0.03B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
ZDJ:CA BMO Dow Jones Industrial .. 0.00 % 0.26 %

-0.91 (-1.96%)

USD0.29B
ZWA:CA BMO Covered Call Dow Jone.. 0.00 % 0.65 %

-0.12 (-0.56%)

USD0.19B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.72 %

-0.03 (-0.27%)

USD0.06B
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

-0.12 (-0.17%)

USD0.38B
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.74 %

N/A

USD0.05B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.12 (+2.29%)

USD0.46B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.46B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

N/A

USD0.43B
CIND:LSE iShares VII PLC - iShares.. 0.00 % 0.33 %

+1.23 (+0.36%)

USD0.86B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.19 %

+0.01 (+0.05%)

USD0.02B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.19% 89% B+ 83% B
Dividend Return 2.59% 50% F 68% D+
Total Return 2.78% 89% B+ 91% A-
Trailing 12 Months  
Capital Gain 5.37% 100% A+ 91% A-
Dividend Return 3.54% 50% F 69% D+
Total Return 8.91% 100% A+ 92% A-
Trailing 5 Years  
Capital Gain 20.89% 71% C- 68% D+
Dividend Return 16.89% 80% B- 78% C+
Total Return 37.78% 71% C- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.76% 75% C 66% D
Dividend Return 3.00% 40% F 72% C-
Total Return 9.76% 75% C 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 12.73% 63% D 79% C+
Risk Adjusted Return 76.69% 63% D 95% A
Market Capitalization 122.18B 88% B+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.42 57% F 45% F
Price/Book Ratio 50.17 14% F 2% F
Price / Cash Flow Ratio 13.19 38% F 18% F
EV/EBITDA 12.44 38% F 18% F
Management Effectiveness  
Return on Equity 123.31% 100% A+ 99% A+
Return on Invested Capital 16.58% 100% A+ 84% B
Return on Assets 10.46% 88% B+ 94% A
Debt to Equity Ratio 495.85% 14% F 5% F
Technical Ratios  
Dividend Yield 3.42% 40% F 56% F
Short Ratio 6.44 13% F 22% F
Short Percent 3.09% 25% F 43% F
Beta 0.56 29% F 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.